Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13318603 | 0.86 | MAPT (0.43) | MAPTCA1ACHECA2MEN1 | |
| SCHEMBL735221 | 0.86 | CA1 (0.53) | MAPTCA1ACHECA2MEN1 | |
| SCHEMBL9240301 | 0.86 | LMNA (0.44) | MAPTCA1ACHECA2MEN1 | |
| SCHEMBL27811655 | 0.83 | LMNA (0.44) | MAPTCA1ACHECA2MEN1 | |
| SCHEMBL27831964 | 0.83 | LMNA (0.44) | MAPTCA1ACHECA2MEN1 | |
| SCHEMBL20279712 | 0.81 | MAPT (0.43) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL20279655 | 0.81 | MAPT (0.43) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL20279765 | 0.81 | MAPT (0.43) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL14556308 | 0.81 | MAPT (0.50) | MAPTACHEMEN1KMT2ACYP1A2 | |
| SCHEMBL21770962 | 0.80 | LMNA (0.47) | MAPTCA1ACHECA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
| US-7276598-B2 | Phosphorylation reagents for improved processes to convert terminal hydroxyl groups of oligonucleotides into phosphate monoesters | SIGMA-ALDRICH CO. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040230047-A1 | Coupling phosphoramidites; phosphates removable in one deprotection step; solid phase synthesis | PROLIGO, LLC (US) | 2004-11-18 | — | — | US | disclosed |
| US-20030162957-A1 | Protected deoxyadenosines and deoxyguanosines | HONEYWELL INTERNATIONAL INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2002068437-A9 | PROTECTED DEOXYADENOSINES AND DEOXYGUANOSINES | HONEYWELL INT INC (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068437-A1 | PROTECTED DEOXYADENOSINES AND DEOXYGUANOSINES | HONEYWELL INTERNATIONAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6414137-B1 | Selective solvent extraction for the purification of protected nucleosides | ALLIEDSIGNAL INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1140957-A1 | SELECTIVE SOLVENT EXTRACTION FOR THE PURIFICATION OF PROTECTED NUCLEOSIDES | AlliedSignal Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000075154-A2 | PROTECTED NUCLEOSIDES | ALLIEDSIGNAL INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000039138-A1 | SELECTIVE SOLVENT EXTRACTION FOR THE PURIFICATION OF PROTECTED NUCLEOSIDES | ALLIEDSIGNAL INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230047-A1 | Coupling phosphoramidites; phosphates removable in one deprotection step; solid phase synthesis | DIMT1, RNGTT, ADAR | MAPT 2088/4885CA1 2283/4885ACHE 1794/4885 |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | MAPT 3910/4885CA1 2612/4885ACHE 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.